Sarclisa (isatuximab-irfc)

Adult Dosing .

Dosage forms:  INJ

Special Note

[drug name clarification]

Info: nonproprietary name = isatuximab-irfc

[uses, dosing may vary]

Info: refer to institution protocols and pkg insert prior to prescribing for uses, premeds, prophylactic antimicrobials, and dosing incl. toxicity-related dose adjustments

multiple myeloma

[relapsed or refractory dz, combo w/ pomalidomide and dexamethasone]

Dose: 10 mg/kg/dose IV x1 on days 1, 8, 15, and 22 of 28-day cycle for cycle 1, then 10 mg/kg/dose IV x1 on days 1, 15 of 28-day cycle starting cycle 2 until dz progression; Info: for patients who have received at least 2 prior tx, incl. lenalidomide and a proteasome inhibitor

[relapsed or refractory dz, combo w/ carfilzomib and dexamethasone]

Dose: 10 mg/kg/dose IV x1 on days 1, 8, 15, and 22 of 28-day cycle for cycle 1, then 10 mg/kg/dose IV x1 on days 1, 15 of 28-day cycle starting cycle 2 until dz progression; Info: for patients who have received 1-3 prior tx

[newly diagnosed dz, combo w/ bortezomib, lenalidomide, and dexamethasone]

Dose: 10 mg/kg/dose IV x1 on days 1, 8, 15, 22, and 29 of 42-day cycle for cycle 1, then 10 mg/kg/dose IV x1 on days 1, 15, and 29 of 42-day cycle for cycles 2-4, then 10 mg/kg/dose IV x1 on days 1, 15 of 28-day cycle for cycles 5-17, then 10 mg/kg/dose IV x1 on day 1 of 28-day cycle starting cycle 18 until dz progression; Info: for patients not eligible for autologous HSCT

renal dosing

[see below]

renal impairment: no adjustment

HD/PD: no adjustment; no supplement

hepatic dosing

[see below]

bilirubin 1-1.5x ULN or AST >ULN: no adjustment; bilirubin >1.5x ULN: not defined

Peds Dosing .

Peds dosing is currently unavailable or not applicable for this drug.